Relmada Therapeutics (RLMD) Tops Q2 EPS by 8c

Relmada Therapeutics (NASDAQ: RLMD) reported Q2 EPS of ($0.11), $0.08 better than the analyst estimate of ($0.19).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• BNP Paribas Exane Downgrades Alcon Inc. (ALC:SW) (ALC) to Neutral
• Capstone Energy+, Inc. (CEPL) Reports Q2 Loss of $0.03